AbCellera Biologics Inc vs United States Copper Index Fund — how do they compare? AbCellera Biologics Inc trades at $9.2 (market cap $2.85B), while United States Copper Index Fund trades at $40.23. Which is the better fit depends on your goals.
| ABCL | CPER | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $9.76 | $40.85 |
52-Week Low | $2.78 | $27.57 |
Enterprise Value | $2.45B | — |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
CPER, the United States Copper Index Fund, trades at $39.9, down 2.11% today, amid a broader bullish technical signal driven by moving averages. Recent news highlights record copper prices fueled by supply disruptions and strong demand from electrification and AI infrastructure. Key support sits at $39, with resistance at $41. Financial ratios are not applicable as this is an ETF tracking copper futures.
The outlook for CPER is positive, supported by structural copper demand trends, but carries risks from potential supply normalization and commodity price volatility. Investors gain exposure to copper's price movements without direct company fundamentals, making it a pure play on industrial metal trends influenced by global economic conditions.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →